A PARP inhibitor, rucaparib, improves cardiac dysfunction in ADP-ribose-acceptor hydrolase 3 (Arh3) deficiency
Preprint in bioRxiv (February 2023)
The most recent citing publications are shown below. View all 41 publications that cite this research output on Dimensions.
Tankyrase Inhibition Attenuates Cardiac Dilatation and Dysfunction in Ischemic Heart Failure
Article in International Journal of Molecular Sciences (September 2022)
Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress
Article in Biomolecules (June 2022)